Arch Therapeutics Inc (ARTH)

[LaddyMan]

Arch Therapeutics (ARTH) Raised to “Hold” at Zacks Investment Research

http://bharatapress.com/2019/01/13/arch-therapeutics-arth-lifted-to-hold-at-zacks-investment-research/

ARCH THERAPEUTICS (ARTH) RAISED TO “HOLD” AT ZACKS INVESTMENT RESEARCH
January 13, 2019 Macon Adams
Arch Therapeutics (ARTH) Raised to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Arch Therapeutics (OTCMKTS:ARTH) from a sell rating to a hold rating in a report published on Thursday morning.

According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “

Several other analysts have also recently weighed in on ARTH. LADENBURG THALM/SH SH initiated coverage on shares of Arch Therapeutics in a research report on Wednesday, September 12th. They set a buy rating on the stock. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the stock a buy rating in a research report on Monday, October 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Arch Therapeutics currently has an average rating of Buy and a consensus price target of $1.75.

Shares of OTCMKTS:ARTH opened at $0.46 on Thursday. Arch Therapeutics has a one year low of $0.26 and a one year high of $0.69. The firm has a market capitalization of $75.64 million, a price-to-earnings ratio of -9.10 and a beta of 0.24.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.

See Also: Treasury Bonds

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com